Tianshan Biotech (300313) Third Quarterly Report Review: It is expected to turn losses into profits throughout the year to create a dual main business pattern
Tianshan Biology (300313): set foot in the media field and open up the space of imagination.
Comments on Tianshan Biological (300313) Quarterly report: the performance is lower than expected and still needs to wait for dawn.
[Southwest Securities] Tianshan Biotech: Performance is lower than expected, we still need to wait for Dawn to arrive
Tianshan Biological (300313) report comments: the performance has reached rock bottom and the future reversal is imminent.
Tianshan Biological (300313) report comments: breeding business drag down performance level beef cattle strategy is actively promoting
Tianshan Biology (300313): 80, 000 mu of land use right to consolidate basic performance reversal period
[southwest Securities] Tianshan Biology: 80,000 mu of land use right to consolidate the foundation, performance reversal can be expected
Research report of Tianshan Biology (300313): performance reversal is imminent and there is still room for future growth.
[southwest Securities] Tianshan Biology: performance reversal is imminent, and future growth is still possible.
Tianshan Biotech (300313) Annual Report Review: The “Big Beef Cow Strategy” continues to push ahead to become the first stock in China's beef industry!
【安信证券】天山生物:“大肉牛战略”继续推进争做中国牛肉产业第一股
天山生物(300313)调研报告:肉牛领域的“温氏” 大肉牛战略框架成型
天山生物(300313):布局牛肉全产业链 争做中国牛肉产业第一股!
【申万宏源】天山生物:肉牛领域的“温氏”,大肉牛战略框架成型
【安信证券】天山生物:布局牛肉全产业链,争做中国牛肉产业第一股!
【申万宏源】天山生物:与百度、中信合作开发牛羊肉众筹项目,维持增持评级
天山生物(300313)调研报告:与百度、中信合作开发牛羊肉众筹项目 维持增持评级
天山生物(300313)中报点评:关注大肉牛战略的落地
【申万宏源】天山生物:拟注入8.45万亩土地,探索肉牛产业链一体化